Valneva sells regulatory ‘fast pass’ for $103M

Vaccine maker Valneva on Monday said it has sold a priority review voucher to an undisclosed buyer for $103 million.

The voucher, a sort of regulatory fast pass, was awarded to Valneva by the Food and Drug Administration alongside its Nov. 9 approval of Ixchiq, the company’s vaccine to prevent disease caused by the chikungunya virus.